Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy

Journal of Surgical Oncology

Volumn 108, Issue 7, 2013, Pages 457-464

  Huang, Ming Yii ^a,b   Tsai, Hsiang Lin ^a,b,c   Lin, Chih Hung ^a   Huang, Ching Wen ^a,b,d   Ma, Cheng Jen ^a,b   Huang, Chun Ming ^a   Chai, Chee Yin ^a,b   Wang, Jaw Yuan ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c FOOYIN UNIVERSITY   (Taiwan)

^d KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

early failure; ERCC1; FOLFOX 4; stage III colorectal cancer; survival

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; COLONOSCOPY; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA REPAIR; EXCISION REPAIR; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERINEURAL INVASION; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY;

EARLY FAILURE; ERCC1; FOLFOX-4; STAGE III COLORECTAL CANCER; SURVIVAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FLUOROURACIL; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84887156576     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23422     Document Type: Article

References (50)

1. Frederiksen BL, Jorgensen T, Brasso K, et al.: Socioeconomic position and participation in colorectal cancer screening. Br J Cancer 2010; 103: 1496-1501.
2. Jemal A, Siegel R, Xu J, et al.: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Weitz J, Koch M, Debus J, et al.: Colorectal cancer. Lancet 2005; 365: 153-165. (Pubitemid 40091806)
4. Department of Health: Cancer registry annual report, Taiwan, Republic of China. 2008; Department of Health, the Executive Yuan, Taipei, Republic of China, 2008.
5. Steele G, Jr.:, Standard postoperative monitoring of patients after primary resection of colon and rectum cancer. Cancer 1993; 71: 4225-4235. (Pubitemid 23169100)
6. Ohlsson B, Breland U, Ekberg H, et al.: Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum 1995; 38: 619-626.
7. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947. (Pubitemid 30644117)
8. Vincenzi B, Santini D, Perrone G, et al.: PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. J Cell Physiol 2012; 227: 927-933.
9. Spindler KL, Andersen RF, Jensen LH, et al.: EGF61A > G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. Ann Oncol 2010; 21: 535-539.
10. Manic S, Gatti L, Carenini N, et al.: Mechanisms controlling sensitivity to platinum complexes: Role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 2003; 3: 21-29. (Pubitemid 36119418)
11. Sancar A:, DNA excision repair. Annu Rev Biochem 1996; 65: 43-81. (Pubitemid 26250604)
12. Petit C, Sancar A:, Nucleotide excision repair: From E. coli to man. Biochimie 1999; 81: 15-25.
13. Altaha R, Liang X, Yu JJ, et al.: Excision repair cross complementing-group 1: Gene expression and platinum resistance. Int J Mol Med 2004; 14: 959-970.
14. Weaver DA, Crawford EL, Warner KA, et al.: ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol cancer 2005; 4: 18.
15. Huang MY, Huang ML, Chen MJ, et al.: Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet Genomics 2011; 21: 18-25.
16. Reed E:, Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998; 24: 331-344. (Pubitemid 28537769)
17. Ferry KV, Hamilton TC, Johnson SW:, Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: Role of ERCC1-XPF. Biochem Pharmacol 2000; 60: 1305-1313.
18. Dabholkar M, Bostick-Bruton F, Weber C, et al.: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992; 84: 1512-1517.
19. Chang IY, Kim MH, Kim HB, et al.: Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 2005; 327: 225-233. (Pubitemid 40051375)
20. Reed E:, ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 2005; 11: 6100-6102. (Pubitemid 41262934)
21. Cunningham D, Atkin W, Lenz HJ, et al.: Colorectal cancer. Lancet 2010; 375: 1030-1047.
22. Buyse M, Piedbois P:, Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 2001; 28: 20-24. (Pubitemid 32173100)
23. Huang MY, Fang WY, Lee SC, et al.: ERCC2 2251A > C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: A preliminary study. BMC cancer 2008; 8: 50.
24. Nozue M, Oshiro Y, Kurata M, et al.: Treatment and prognosis in colorectal cancer patients with bone metastasis. Oncol Rep 2002; 9: 109-112.
25. Longo WE, Johnson FE:, The preoperative assessment and postoperative surveillance of patients with colon and rectal cancer. Surg Clin North Am 2002; 82: 1091-1108. (Pubitemid 35463086)
26. Watanabe T, Kobunai T, Yamamoto Y, et al.: Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. Clin Transl Oncol 2011; 13: 419-425.
27. McLeod HL, Sargent DJ, Marsh S, et al.: Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: Results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 2010; 28: 3227-3233.
28. Lu CY, Tsai HL, Uen YH, et al.: Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer. Br J Cancer 2013; 108: 791-797.
29. Kelly H, Goldberg RM:, Systemic therapy for metastatic colorectal cancer: Current options, current evidence. J Clin Oncol 2005; 23: 4553-4560. (Pubitemid 46196586)
30. Raymond E, Chaney SG, Taamma A, et al.: Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053-1071. (Pubitemid 28518143)
31. Raymond E, Faivre S, Woynarowski JM, et al.: Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 1998; 25: 4-12. (Pubitemid 28248696)
32. Graham MA, Lockwood GF, Greenslade D, et al.: Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 2000; 6: 1205-1218. (Pubitemid 30226200)
33. Raymond E, Faivre S, Chaney S, et al.: Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002; 1: 227-235.
34. Rosell R, Mendez P, Isla D, et al.: Platinum resistance related to a functional NER pathway. J Thorac Oncol 2007; 2: 1063-1066. (Pubitemid 350307897)
35. Gossage L, Madhusudan S:, Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 2007; 33: 565-577. (Pubitemid 47355341)
36. Kim SH, Kwon HC, Oh SY, et al.: Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol 2009; 32: 38-43.
37. Xia Y, Hu C, Zhang M, et al.: Relationship between ERCC1 expression and cisplatin intervention in human lung adenocarcinoma cell lines. Zhongguo Fei Ai Za Zhi 2007; 10: 362-365. (Pubitemid 350072536)
38. Seetharam RN, Sood A, Basu-Mallick A, et al.: Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells. Anticancer Res 2010; 30: 2531-2538.
39. Schuster R, Max N, Mann B, et al.: Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers. Int J Cancer 2004; 108: 219-227. (Pubitemid 37541774)
40. Weidner N, Carroll PR, Flax J, et al.: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-409. (Pubitemid 24058195)
41. Yeh CS, Wang JY, Wu CH, et al.: Molecular detection of circulating cancer cells in the peripheral blood of patients with colorectal cancer by using membrane array with a multiple mRNA marker panel. Int J Oncol 2006; 28: 411-420.
42. Park DJ, Stoehlmacher J, Zhang W, et al.: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61: 8654-8658. (Pubitemid 34013872)
43. Lai JI, Tzeng CH, Chen PM, et al.: Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 2009; 100: 1261-1266.
44. Fortini P, Pascucci B, Parlanti E, et al.: The base excision repair: Mechanisms and its relevance for cancer susceptibility. Biochimie 2003; 85: 1053-1071. (Pubitemid 38142361)
45. Gangurde H, Chavan N, Mundada A, et al.: Biodegradable chitosan-based ambroxol hydrochloride microspheres: Effect of cross-linking agents. J Young Pharm 2011; 3: 9-14.
46. Lv H, Li Q, Qiu W, et al.: Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer. Pathol Oncol Res 2012; 18: 1009-1014.
47. Wang S, Wu X, Chen Y, et al.: Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer. Clin Cancer Res 2012; 18: 2987-2996.
48. Ang MK, Patel MR, Yin XY, et al.: High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2011; 17: 6542-6552.
49. Filiz AI, Sucullu I, Kurt Y, et al.: Persistent high postoperative carcinoembryonic antigen in colorectal cancer patients-Is it important ? Clinics (Sao Paulo) 2009; 64: 287-294.
50. Blazquez AB, Mayorga C, Blanca-Lopez N, et al.: Sublingual immunotherapy and oral mucosal langerhans cells. Immunotherapy 2011; 3: 9-11.